King Wealth Theravance Biopharma, Inc. Transaction History

King Wealth

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$8.41 - $10.34 $647,570 - $796,180	-77,000 Reduced 63.11%	45,000 $408,000
Q1 2022 May 12, 2022	BUY	$8.33 - $12.96 $907,970 - $1.41 Million	109,000 Added 838.46%	122,000 $1.17 Million
Q3 2021 Nov 12, 2021	SELL	$6.77 - $14.41 $67,700 - $144,100	-10,000 Reduced 43.48%	13,000 $96,000
Q2 2020 Aug 13, 2020	BUY	$20.64 - $30.69 $169,248 - $251,658	8,200 Added 55.41%	23,000 $483,000
Q1 2020 May 13, 2020	SELL	$17.84 - $31.21 $137,368 - $240,317	-7,700 Reduced 34.22%	14,800 $342,000
Q4 2019 Feb 13, 2020	BUY	$16.12 - $25.89 $80,600 - $129,450	5,000 Added 28.57%	22,500 $583,000
Q3 2019 Nov 13, 2019	SELL	$16.51 - $23.78 $115,570 - $166,460	-7,000 Reduced 28.57%	17,500 $341,000
Q2 2019 Aug 13, 2019	BUY	$15.6 - $25.15 $117,000 - $188,625	7,500 Added 44.12%	24,500 $400,000
Q1 2019 May 13, 2019	BUY	$22.57 - $28.15 $383,690 - $478,550	17,000 New	17,000 $385,000

122

47.3M

200

12.8K

Ticker TBPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,782,400
Market Cap $640M
Description
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...

Get notified when there are updates to the investment portfolio of King Wealth, based on Form 13F filings with the SEC.

Stay updated on King Wealth with notifications on news.